DE69941116D1 - G von gdf-8 - Google Patents
G von gdf-8Info
- Publication number
- DE69941116D1 DE69941116D1 DE69941116T DE69941116T DE69941116D1 DE 69941116 D1 DE69941116 D1 DE 69941116D1 DE 69941116 T DE69941116 T DE 69941116T DE 69941116 T DE69941116 T DE 69941116T DE 69941116 D1 DE69941116 D1 DE 69941116D1
- Authority
- DE
- Germany
- Prior art keywords
- gdf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8449098P | 1998-05-06 | 1998-05-06 | |
| PCT/US1999/010089 WO1999056768A1 (en) | 1998-05-06 | 1999-05-06 | Methods for treating diabetes by inhibiting gdf-8 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69941116D1 true DE69941116D1 (de) | 2009-08-27 |
Family
ID=22185291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69941116T Expired - Lifetime DE69941116D1 (de) | 1998-05-06 | 1999-05-06 | G von gdf-8 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US6368597B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1075272B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4544742B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU765214B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2331410C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69941116D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2330062T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999056768A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7510851B2 (en) * | 2001-12-17 | 2009-03-31 | Metabolex, Inc. | Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia |
| BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US6908632B1 (en) | 2002-04-19 | 2005-06-21 | Pharmanex, Llc | Blood glucose modulating compositions and methods |
| AU2003267246A1 (en) * | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2003297460A1 (en) * | 2002-12-19 | 2004-07-14 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS |
| AU2003301195B2 (en) * | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| CA2558478A1 (en) * | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) * | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| MX2007000976A (es) * | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| MX2007008132A (es) * | 2004-12-30 | 2007-07-20 | Schering Plough Ltd | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes. |
| EP1864139A2 (en) * | 2005-03-23 | 2007-12-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
| CA2538208A1 (en) * | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| KR101135220B1 (ko) * | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| HRP20130320T1 (en) * | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
| KR20120023787A (ko) | 2009-05-22 | 2012-03-13 | 가부시키가이샤 에리나 | 대사증후군의 예방제 및/또는 치료제 |
| WO2011087946A1 (en) | 2010-01-15 | 2011-07-21 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| PH12013500315A1 (en) | 2010-08-16 | 2013-04-29 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| MY177331A (en) * | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
| CN104931327B (zh) * | 2015-03-24 | 2018-10-19 | 重庆医科大学 | 微米级生物材料石蜡切片方法 |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| IL276921B2 (en) | 2018-03-01 | 2025-12-01 | Regeneron Pharma | Methods for altering body composition |
| WO2020075845A1 (ja) * | 2018-10-12 | 2020-04-16 | シーシーアイホールディングス株式会社 | クラスiのグルコーストランスポーター(glut)の発現誘導剤、並びにこれを用いた医薬組成物および飲食品組成物 |
| CN110408616B (zh) * | 2019-07-09 | 2021-06-15 | 中南民族大学 | GLUT4基因敲除的sgRNA、A549细胞系及其构建方法 |
| KR20220054608A (ko) | 2019-09-03 | 2022-05-03 | 노파르티스 아게 | ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2157577C (en) * | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
| WO1999006559A1 (en) * | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| EE200200025A (et) * | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
-
1999
- 1999-05-06 ES ES99925578T patent/ES2330062T3/es not_active Expired - Lifetime
- 1999-05-06 DE DE69941116T patent/DE69941116D1/de not_active Expired - Lifetime
- 1999-05-06 CA CA002331410A patent/CA2331410C/en not_active Expired - Lifetime
- 1999-05-06 EP EP99925578A patent/EP1075272B1/en not_active Expired - Lifetime
- 1999-05-06 US US09/305,989 patent/US6368597B1/en not_active Expired - Lifetime
- 1999-05-06 AU AU41832/99A patent/AU765214B2/en not_active Ceased
- 1999-05-06 WO PCT/US1999/010089 patent/WO1999056768A1/en not_active Ceased
- 1999-05-06 JP JP2000546792A patent/JP4544742B2/ja not_active Expired - Lifetime
-
2001
- 2001-11-19 US US09/988,835 patent/US20020031517A1/en not_active Abandoned
-
2005
- 2005-06-16 US US11/155,336 patent/US20060121035A1/en not_active Abandoned
-
2008
- 2008-02-14 US US12/070,067 patent/US9150643B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 US US14/838,490 patent/US20160122424A1/en not_active Abandoned
-
2017
- 2017-08-24 US US15/685,582 patent/US20180134779A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160122424A1 (en) | 2016-05-05 |
| HK1038497A1 (en) | 2002-03-22 |
| US20020031517A1 (en) | 2002-03-14 |
| AU765214B2 (en) | 2003-09-11 |
| AU4183299A (en) | 1999-11-23 |
| CA2331410C (en) | 2009-07-14 |
| US20180134779A1 (en) | 2018-05-17 |
| ES2330062T3 (es) | 2009-12-03 |
| US9150643B2 (en) | 2015-10-06 |
| JP2002513768A (ja) | 2002-05-14 |
| EP1075272B1 (en) | 2009-07-15 |
| WO1999056768A1 (en) | 1999-11-11 |
| CA2331410A1 (en) | 1999-11-11 |
| JP4544742B2 (ja) | 2010-09-15 |
| US6368597B1 (en) | 2002-04-09 |
| US20090035297A1 (en) | 2009-02-05 |
| EP1075272A1 (en) | 2001-02-14 |
| US20060121035A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69928195D1 (de) | Komplettierung von Untrerdruck-Bohrlöchern | |
| CY2012029I2 (el) | Nεα μορφη της 5-ομεπραζολης | |
| ID29021A (id) | Komposisi galantamina pelepasan terkontrol | |
| ID27092A (id) | Pembuatan ftalat anhidrida | |
| ID29028A (id) | Pirolopirimidina sebagai penghambat protein kinase | |
| DE69837906D1 (de) | Insektizides proteintoxin von xenorhabus | |
| DE60136181D1 (de) | 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden | |
| PT945132E (pt) | Composicao de ibuprofeno | |
| EP1098968A4 (en) | NITRILASE APPROVALS | |
| ID24638A (id) | Senyawa-senyawa anti aritmia bispidina | |
| IT1304793B1 (it) | Miscela di stabilizzanti | |
| PT1100326E (pt) | Microcapsulas de libertacao activada por bases | |
| ATE231521T1 (de) | Kristalline formen von eto2c-ch2-(r)cgl-aze-pab- oh | |
| NO984662L (no) | Vann-i-olje-emulsjonsgj°dningsstoff-sammensetninger | |
| ID24374A (id) | Komposisi-komposisi parenteral alatrofloksasin | |
| IT1304794B1 (it) | Miscela di stabilizzanti | |
| DE69806558D1 (de) | Stabilisierung von 3-Isothiazolonlösungen | |
| DE60107074D1 (de) | Kristallin form ii von cabergolin | |
| DE69913556D1 (de) | Herstellung von aminen | |
| NO20002555D0 (no) | Skjøt | |
| DE69813402D1 (de) | Herstellung von Alkylhalogensilanen | |
| ID28032A (id) | TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2 | |
| DE60006799D1 (de) | Oralverabreichbare lösung von prucaloprid | |
| DE69927626D1 (de) | Ausführung von Permutationen | |
| DE69811256D1 (de) | Polymorphe modifikationen von dofetilid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |